Jasper therapeutics, inc.JSPR.US Overview
JSPR Overall Performance
JSPR AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
JSPR Key Information
JSPR Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
JSPR Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
JSPR Profile
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and stem cell engineering to allow expanded use of stem cell transplantation and ex vivo gene therapy, a technique in which genetic manipulation of cells is performed outside the body prior to transplantation. The company's lead product candidate is JSP191, which is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. The company is based in Redwood City, California.
Price of JSPR
JSPR FAQ
When is JSPR's latest earnings report released?
The most recent financial report for Jasper therapeutics, inc. (JSPR) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating JSPR's short-term business performance and financial health. For the latest updates on JSPR's earnings releases, visit this page regularly.
How much cash does JSPR have?
At the end of the period, Jasper therapeutics, inc. (JSPR) held Total Cash and Cash Equivalents of 51.32M, accounting for 0.89 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is JSPR's EPS continuing to grow?
According to the past four quarterly reports, Jasper therapeutics, inc. (JSPR)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.13. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of JSPR?
Jasper therapeutics, inc. (JSPR)'s Free Cash Flow (FCF) for the period is -17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 18.66% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.